Bank Of New York Mellon Corp Immunic, Inc. Transaction History

Bank Of New York Mellon Corp

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 09, 2023	BUY	$1.35 - $2.87 $36,501 - $77,599	27,038 New	27,038 $40.3 Million
Q4 2022 Feb 14, 2023	BUY	$1.13 - $10.8 $30,552 - $292,010	27,038 New	27,038 $37,000
Q3 2022 Nov 14, 2022	SELL	$3.0 - $5.49 $45 - $82	-15 Reduced 0.06%	27,038 $85,000
Q2 2022 Aug 15, 2022	SELL	$3.13 - $12.25 $161,630 - $632,577	-51,639 Reduced 65.62%	27,053 $94,000
Q1 2022 May 11, 2022	SELL	$9.54 - $14.26 $27,103 - $40,512	-2,841 Reduced 3.48%	78,692 $889,000
Q4 2021 Feb 11, 2022	BUY	$7.34 - $10.25 $83,066 - $115,999	11,317 Added 16.12%	81,533 $779,000
Q3 2021 Nov 12, 2021	BUY	$8.05 - $13.29 $59,497 - $98,226	7,391 Added 11.76%	70,216 $621,000
Q2 2021 Aug 11, 2021	BUY	$11.76 - $16.85 $258,661 - $370,615	21,995 Added 53.87%	62,825 $770,000
Q1 2021 May 13, 2021	BUY	$14.21 - $25.3 $5,200 - $9,259	366 Added 0.9%	40,830 $650,000
Q4 2020 Feb 09, 2021	BUY	$14.8 - $20.37 $76,308 - $105,027	5,156 Added 14.6%	40,464 $618,000
Q3 2020 Nov 12, 2020	BUY	$11.74 - $22.0 $414,515 - $776,776	35,308 New	35,308 $655,000

56.2M

100

350K

Ticker IMUX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,565,000
Market Cap $30.6M
Description
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and oth...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.